Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Erasca, Inc. (ERAS : NSDQ)

• Company Description    Erasca Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca Inc. is based in SAN DIEGO. Number of Employees: 103

• Price / Volume Information    Yesterday's Closing Price: $1.44 Daily Weekly Monthly 20 Day Moving Average: 1,241,760 shares Shares Outstanding: 283.29 (millions) Market Capitalization: $407.93 (millions) Beta: 1.05 52 Week High: $3.45 52 Week Low: $1.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.28% -13.25% 12 Week 35.21% 13.44% Year To Date -42.63% -46.26%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3115 MERRYFIELD ROW SUITE 300 - SAN DIEGO,CA 92121 USA ph: 858-465-6511 fax: - ir@erasca.com http://www.erasca.com

• General Corporate Information    Officers Jonathan E. Lim - Chief Executive Officer; Chairman and Co-Founder David M. Chacko - Chief Financial Officer and Chief Business Officer Michael D. Varney - Chair of Research and Development and Director James A. Bristol - Director Alexander W. Casdin - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29479A108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 283.29 Most Recent Split Date: (:1) Beta: 1.05 Market Capitalization: $407.93 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.50 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.02 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 52.17% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -36.56 12/31/24 - -40.09 ROA 06/30/25 - - 03/31/25 - -31.08 12/31/24 - -33.55 Current Ratio 06/30/25 - - 03/31/25 - 12.35 12/31/24 - 9.84 Quick Ratio 06/30/25 - - 03/31/25 - 12.35 12/31/24 - 9.84 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 1.41 12/31/24 - 1.50 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©